AU2013263292B2 - Pharmaceutical compositions for the delivery of substantially water-insoluble drugs - Google Patents

Pharmaceutical compositions for the delivery of substantially water-insoluble drugs Download PDF

Info

Publication number
AU2013263292B2
AU2013263292B2 AU2013263292A AU2013263292A AU2013263292B2 AU 2013263292 B2 AU2013263292 B2 AU 2013263292B2 AU 2013263292 A AU2013263292 A AU 2013263292A AU 2013263292 A AU2013263292 A AU 2013263292A AU 2013263292 B2 AU2013263292 B2 AU 2013263292B2
Authority
AU
Australia
Prior art keywords
och
pct
water
paclitaxel
hybrid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013263292A
Other languages
English (en)
Other versions
AU2013263292A1 (en
Inventor
Maninder SANDHU
Mewa Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2013263292A1 publication Critical patent/AU2013263292A1/en
Application granted granted Critical
Publication of AU2013263292B2 publication Critical patent/AU2013263292B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Emergency Medicine (AREA)
AU2013263292A 2012-05-16 2013-04-09 Pharmaceutical compositions for the delivery of substantially water-insoluble drugs Active AU2013263292B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261647727P 2012-05-16 2012-05-16
US61/647,727 2012-05-16
PCT/US2013/035792 WO2013172999A1 (en) 2012-05-16 2013-04-09 Pharmaceutical compositions for the delivery of substantially water-insoluble drugs

Publications (2)

Publication Number Publication Date
AU2013263292A1 AU2013263292A1 (en) 2015-01-15
AU2013263292B2 true AU2013263292B2 (en) 2018-03-08

Family

ID=49584153

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013263292A Active AU2013263292B2 (en) 2012-05-16 2013-04-09 Pharmaceutical compositions for the delivery of substantially water-insoluble drugs

Country Status (8)

Country Link
US (1) US9895322B2 (enExample)
EP (1) EP2849770B1 (enExample)
JP (1) JP6247685B2 (enExample)
AU (1) AU2013263292B2 (enExample)
CA (1) CA2873572C (enExample)
IN (1) IN2014DN10322A (enExample)
MX (1) MX374014B (enExample)
WO (1) WO2013172999A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9114238B2 (en) 2007-04-16 2015-08-25 Corium International, Inc. Solvent-cast microprotrusion arrays containing active ingredient
WO2009048607A1 (en) 2007-10-10 2009-04-16 Corium International, Inc. Vaccine delivery via microneedle arrays
US9687641B2 (en) 2010-05-04 2017-06-27 Corium International, Inc. Method and device for transdermal delivery of parathyroid hormone using a microprojection array
IN2014DN10322A (enExample) 2012-05-16 2015-08-07 Mewa Singh
JP6865524B2 (ja) 2012-12-21 2021-04-28 コリウム， インコーポレイテッド 治療剤を送達するためのマイクロアレイおよび使用方法
JP6487899B2 (ja) 2013-03-12 2019-03-20 コリウム インターナショナル， インコーポレイテッド 微小突起アプリケータ
WO2014150285A2 (en) 2013-03-15 2014-09-25 Corium International, Inc. Multiple impact microprojection applicators and methods of use
AU2014237279B2 (en) 2013-03-15 2018-11-22 Corium Pharma Solutions, Inc. Microarray with polymer-free microstructures, methods of making, and methods of use
EP2968118B1 (en) 2013-03-15 2022-02-09 Corium, Inc. Microarray for delivery of therapeutic agent and methods of use
US10213391B2 (en) 2014-05-06 2019-02-26 Mewa Singh Pharmaceutical compositions comprising hemp and turmeric to treat pain and inflammation
EP3188714A1 (en) 2014-09-04 2017-07-12 Corium International, Inc. Microstructure array, methods of making, and methods of use
US20160346219A1 (en) 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
WO2017004067A1 (en) 2015-06-29 2017-01-05 Corium International, Inc. Microarray for delivery of therapeutic agent, methods of use, and methods of making
WO2017031261A1 (en) * 2015-08-20 2017-02-23 Mewa Singh Polyphenolic polymer to make water-insoluble molecules become water-soluble
WO2018118197A1 (en) * 2016-12-21 2018-06-28 Richard Postrel Healthier aging in domesticated animals
WO2019211159A1 (en) 2018-05-02 2019-11-07 Ferring B.V. Improved pharmaceutical formulations
IL261132A (en) 2018-08-13 2018-11-04 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
CN109806241A (zh) * 2019-03-04 2019-05-28 聊城大学 一种双药白蛋白纳米粒及制备工艺
JP7748878B2 (ja) * 2019-06-28 2025-10-03 パスポート テクノロジーズ、インコーポレイテッド 形成された経路を介した透過物送達パッチ
US12439951B2 (en) * 2019-10-09 2025-10-14 Nicoventures Trading Limited Aerosolizable material with cannabinoid and carrier constituent
US20210393541A1 (en) * 2020-06-19 2021-12-23 City University Of Hong Kong Preparation of nanoparticles using modified ice-template
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
CA3217137A1 (en) 2021-04-29 2022-11-03 Christopher Adair Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006107334A1 (en) * 2005-03-31 2006-10-12 Smithkline Beecham Corporation Dissolvable tooth whitening strip
US20080107749A1 (en) * 2006-10-05 2008-05-08 Arniban Maitra Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles
WO2010033692A1 (en) * 2008-09-17 2010-03-25 University Of Wyoming Curcumin-containing polymers and water soluble curcumin derivatives as prodrugs or prodrug carriers
WO2010039496A2 (en) * 2008-09-23 2010-04-08 The Regents Of The University Of California Nanocarriers for drug delivery

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
GB9405593D0 (en) 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
US5731356A (en) 1994-03-22 1998-03-24 Zeneca Limited Pharmaceutical compositions of propofol and edetate
US6147122A (en) 1998-02-10 2000-11-14 Gensia Sincor Inc. Propofol composition containing sulfite
US6028108A (en) 1998-10-22 2000-02-22 America Home Products Corporation Propofol composition comprising pentetate
US6177477B1 (en) 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6100302A (en) 1999-04-05 2000-08-08 Baxter International Inc. Propofol formulation with enhanced microbial characteristics
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
US6730330B2 (en) 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
AU2003231134A1 (en) * 2002-04-26 2003-11-10 Teva Pharmaceutical Industries, Ltd. Microparticle pharmaceutical compositions for intratumoral delivery
DK1585548T3 (en) 2002-12-09 2018-09-03 Abraxis Bioscience Llc COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
CA2540104A1 (en) * 2003-09-30 2005-04-07 Solubest Ltd. Water soluble nanoparticles comprising inclusion complexes
CN101273066B (zh) * 2005-09-09 2013-10-16 郑特来 用于递送抗癌剂的水溶性壳聚糖纳米颗粒及其制备方法
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
US8735374B2 (en) 2009-07-31 2014-05-27 Intelgenx Corp. Oral mucoadhesive dosage form
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US8501248B1 (en) 2010-11-02 2013-08-06 Seven Consulting, Inc. Botanical composition and method for treating pain and discomfort of various conditions
BR112013032675A2 (pt) 2011-06-19 2017-08-08 Vaxine Pty Ltd composição adjuvante de vacina compreendendo partículas de inulina
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
WO2013108254A1 (en) 2012-01-19 2013-07-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Formulation and method for increasing oral bioavailability of drugs
IN2014DN10322A (enExample) 2012-05-16 2015-08-07 Mewa Singh

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006107334A1 (en) * 2005-03-31 2006-10-12 Smithkline Beecham Corporation Dissolvable tooth whitening strip
US20080107749A1 (en) * 2006-10-05 2008-05-08 Arniban Maitra Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles
WO2010033692A1 (en) * 2008-09-17 2010-03-25 University Of Wyoming Curcumin-containing polymers and water soluble curcumin derivatives as prodrugs or prodrug carriers
WO2010039496A2 (en) * 2008-09-23 2010-04-08 The Regents Of The University Of California Nanocarriers for drug delivery

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GANTA SRINIVAS et al.: "Coadministration of Paclitaxel and Curcumin in Nanoemulsion Formulations To Overcome Multidrug Resistance in Tumor Cells", MOLECULAR PHARMACEUTICS, vol. 6, no. 3, May 2009, pages 928-939, ISSN: 1543-8384 *

Also Published As

Publication number Publication date
CA2873572C (en) 2021-07-06
MX2014013826A (es) 2018-04-24
CA2873572A1 (en) 2013-11-21
IN2014DN10322A (enExample) 2015-08-07
AU2013263292A1 (en) 2015-01-15
US9895322B2 (en) 2018-02-20
EP2849770A4 (en) 2016-03-23
JP6247685B2 (ja) 2017-12-13
JP2015517522A (ja) 2015-06-22
EP2849770A1 (en) 2015-03-25
WO2013172999A1 (en) 2013-11-21
EP2849770B1 (en) 2020-07-29
MX374014B (es) 2020-07-24
US20150080353A1 (en) 2015-03-19

Similar Documents

Publication Publication Date Title
AU2013263292B2 (en) Pharmaceutical compositions for the delivery of substantially water-insoluble drugs
US11622937B2 (en) Polyphenolic polymer to make water-insoluble molecules become water-soluble
Slavkova et al. Orodispersible drug formulations for children and elderly
Hirani et al. Orally disintegrating tablets: a review
JP5681693B2 (ja) 動物における障害を治療および予防するための薬剤組成物の経粘膜投与
US20120225118A1 (en) Compositions for delivery of insoluble agents
US20180085308A1 (en) Sustained release cannabinoid formulations
WO2018112119A1 (en) Non-aqueous delta9-tetrahydrocannabinol oral liquid formulations
US20180263953A1 (en) Sustained Release Cannabinoid Formulations
Beri et al. Development of fast disintegration tablets as oral drug delivery system-A review
JP2022509463A (ja) 非クルクミノイドの水溶性粒子とクルクミノイドの水溶性粒子から構成される製剤
WO2023279137A1 (en) A composition and application thereof
US20180263954A1 (en) Sustained Release Cannabinoid Formulations
CN107427488A (zh) 鞣花酸二水合物在食品和保健品中的用途
US9283211B1 (en) Oral rapamycin preparation and use for stomatitis
WO2015175479A1 (en) Pharmaceutical composition
EP3131546B1 (en) Oral rapamycin preparation for use in treating feline chronic gingivo- stomatitis (fcgs)
Das 16 Recent Advancement
WO2025160293A1 (en) Berberine compositions with enhanced oral bioavailability and uses thereof
Prawinata Development of cannabis extract active coating on granules with taste masking polymer via fluidized bed
Hossain et al. Recent Advancement in the Use of Nano-Nutraceuticals in Medicine
JP2025180213A (ja) 組成物
JP2025097148A (ja) 医薬品
JP2022084568A (ja) 医薬組成物
JP2023551954A (ja) トコトリエノールの経粘膜送達

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)